Perspectives on validation of high-throughput assays supporting 21st century toxicity testing

Richard Judson, Robert Kavlock, Matthew Martin, David Reif, Keith Houck, Thomas Knudsen, Ann Richard, Raymond R. Tice, Maurice Whelan, Menghang Xia, Ruili Huang, Christopher Austin, George Daston, Thomas Hartung, John R. Fowle, William Wooge, Weida Tong, David Dix

Research output: Contribution to journalArticle

Abstract

In vitro high-throughput screening (HTS) assays are seeing increasing use in toxicity testing. HTS assays can simultaneously test many chemicals but have seen limited use in the regulatory arena, in part because of the need to undergo rigorous, time-consuming formal validation. Here we discuss streamlining the validation process, specifically for prioritization applications. By prioritization, we mean a process in which less complex, less expensive, and faster assays are used to prioritize which chemicals are subjected first to more complex, expensive, and slower guideline assays. Data from the HTS prioritization assays is intended to provide a priori evidence that certain chemicals have the potential to lead to the types of adverse effects that the guideline tests are assessing. The need for such prioritization approaches is driven by the fact that there are tens of thousands of chemicals to which people are exposed, but the yearly throughput of most guideline assays is small in comparison. The streamlined validation process would continue to ensure the reliability and relevance of assays for this application. We discuss the following practical guidelines: (1) follow current validation practice to the extent possible and practical; (2) make increased use of reference compounds to better demonstrate assay reliability and relevance; (3) de-emphasize the need for cross-laboratory testing; and (4) implement a web-based, transparent, and expedited peer review process.

Original languageEnglish (US)
Pages (from-to)51-66
Number of pages16
JournalAltex
Volume30
Issue number1
StatePublished - 2013

Fingerprint

High-Throughput Screening Assays
Guidelines
Peer Review

Keywords

  • High-throughput screening
  • In vitro
  • Validation

ASJC Scopus subject areas

  • Medical Laboratory Technology
  • Pharmacology

Cite this

Judson, R., Kavlock, R., Martin, M., Reif, D., Houck, K., Knudsen, T., ... Dix, D. (2013). Perspectives on validation of high-throughput assays supporting 21st century toxicity testing. Altex, 30(1), 51-66.

Perspectives on validation of high-throughput assays supporting 21st century toxicity testing. / Judson, Richard; Kavlock, Robert; Martin, Matthew; Reif, David; Houck, Keith; Knudsen, Thomas; Richard, Ann; Tice, Raymond R.; Whelan, Maurice; Xia, Menghang; Huang, Ruili; Austin, Christopher; Daston, George; Hartung, Thomas; Fowle, John R.; Wooge, William; Tong, Weida; Dix, David.

In: Altex, Vol. 30, No. 1, 2013, p. 51-66.

Research output: Contribution to journalArticle

Judson, R, Kavlock, R, Martin, M, Reif, D, Houck, K, Knudsen, T, Richard, A, Tice, RR, Whelan, M, Xia, M, Huang, R, Austin, C, Daston, G, Hartung, T, Fowle, JR, Wooge, W, Tong, W & Dix, D 2013, 'Perspectives on validation of high-throughput assays supporting 21st century toxicity testing', Altex, vol. 30, no. 1, pp. 51-66.
Judson R, Kavlock R, Martin M, Reif D, Houck K, Knudsen T et al. Perspectives on validation of high-throughput assays supporting 21st century toxicity testing. Altex. 2013;30(1):51-66.
Judson, Richard ; Kavlock, Robert ; Martin, Matthew ; Reif, David ; Houck, Keith ; Knudsen, Thomas ; Richard, Ann ; Tice, Raymond R. ; Whelan, Maurice ; Xia, Menghang ; Huang, Ruili ; Austin, Christopher ; Daston, George ; Hartung, Thomas ; Fowle, John R. ; Wooge, William ; Tong, Weida ; Dix, David. / Perspectives on validation of high-throughput assays supporting 21st century toxicity testing. In: Altex. 2013 ; Vol. 30, No. 1. pp. 51-66.
@article{22b2416938fc474294c5be6b274e4c3c,
title = "Perspectives on validation of high-throughput assays supporting 21st century toxicity testing",
abstract = "In vitro high-throughput screening (HTS) assays are seeing increasing use in toxicity testing. HTS assays can simultaneously test many chemicals but have seen limited use in the regulatory arena, in part because of the need to undergo rigorous, time-consuming formal validation. Here we discuss streamlining the validation process, specifically for prioritization applications. By prioritization, we mean a process in which less complex, less expensive, and faster assays are used to prioritize which chemicals are subjected first to more complex, expensive, and slower guideline assays. Data from the HTS prioritization assays is intended to provide a priori evidence that certain chemicals have the potential to lead to the types of adverse effects that the guideline tests are assessing. The need for such prioritization approaches is driven by the fact that there are tens of thousands of chemicals to which people are exposed, but the yearly throughput of most guideline assays is small in comparison. The streamlined validation process would continue to ensure the reliability and relevance of assays for this application. We discuss the following practical guidelines: (1) follow current validation practice to the extent possible and practical; (2) make increased use of reference compounds to better demonstrate assay reliability and relevance; (3) de-emphasize the need for cross-laboratory testing; and (4) implement a web-based, transparent, and expedited peer review process.",
keywords = "High-throughput screening, In vitro, Validation",
author = "Richard Judson and Robert Kavlock and Matthew Martin and David Reif and Keith Houck and Thomas Knudsen and Ann Richard and Tice, {Raymond R.} and Maurice Whelan and Menghang Xia and Ruili Huang and Christopher Austin and George Daston and Thomas Hartung and Fowle, {John R.} and William Wooge and Weida Tong and David Dix",
year = "2013",
language = "English (US)",
volume = "30",
pages = "51--66",
journal = "ALTEX : Alternativen zu Tierexperimenten",
issn = "1868-596X",
publisher = "Elsevier GmbH",
number = "1",

}

TY - JOUR

T1 - Perspectives on validation of high-throughput assays supporting 21st century toxicity testing

AU - Judson, Richard

AU - Kavlock, Robert

AU - Martin, Matthew

AU - Reif, David

AU - Houck, Keith

AU - Knudsen, Thomas

AU - Richard, Ann

AU - Tice, Raymond R.

AU - Whelan, Maurice

AU - Xia, Menghang

AU - Huang, Ruili

AU - Austin, Christopher

AU - Daston, George

AU - Hartung, Thomas

AU - Fowle, John R.

AU - Wooge, William

AU - Tong, Weida

AU - Dix, David

PY - 2013

Y1 - 2013

N2 - In vitro high-throughput screening (HTS) assays are seeing increasing use in toxicity testing. HTS assays can simultaneously test many chemicals but have seen limited use in the regulatory arena, in part because of the need to undergo rigorous, time-consuming formal validation. Here we discuss streamlining the validation process, specifically for prioritization applications. By prioritization, we mean a process in which less complex, less expensive, and faster assays are used to prioritize which chemicals are subjected first to more complex, expensive, and slower guideline assays. Data from the HTS prioritization assays is intended to provide a priori evidence that certain chemicals have the potential to lead to the types of adverse effects that the guideline tests are assessing. The need for such prioritization approaches is driven by the fact that there are tens of thousands of chemicals to which people are exposed, but the yearly throughput of most guideline assays is small in comparison. The streamlined validation process would continue to ensure the reliability and relevance of assays for this application. We discuss the following practical guidelines: (1) follow current validation practice to the extent possible and practical; (2) make increased use of reference compounds to better demonstrate assay reliability and relevance; (3) de-emphasize the need for cross-laboratory testing; and (4) implement a web-based, transparent, and expedited peer review process.

AB - In vitro high-throughput screening (HTS) assays are seeing increasing use in toxicity testing. HTS assays can simultaneously test many chemicals but have seen limited use in the regulatory arena, in part because of the need to undergo rigorous, time-consuming formal validation. Here we discuss streamlining the validation process, specifically for prioritization applications. By prioritization, we mean a process in which less complex, less expensive, and faster assays are used to prioritize which chemicals are subjected first to more complex, expensive, and slower guideline assays. Data from the HTS prioritization assays is intended to provide a priori evidence that certain chemicals have the potential to lead to the types of adverse effects that the guideline tests are assessing. The need for such prioritization approaches is driven by the fact that there are tens of thousands of chemicals to which people are exposed, but the yearly throughput of most guideline assays is small in comparison. The streamlined validation process would continue to ensure the reliability and relevance of assays for this application. We discuss the following practical guidelines: (1) follow current validation practice to the extent possible and practical; (2) make increased use of reference compounds to better demonstrate assay reliability and relevance; (3) de-emphasize the need for cross-laboratory testing; and (4) implement a web-based, transparent, and expedited peer review process.

KW - High-throughput screening

KW - In vitro

KW - Validation

UR - http://www.scopus.com/inward/record.url?scp=84877297399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877297399&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 51

EP - 66

JO - ALTEX : Alternativen zu Tierexperimenten

JF - ALTEX : Alternativen zu Tierexperimenten

SN - 1868-596X

IS - 1

ER -